NEWSROOM

NASDAQ

Sono-Tek Completes Senior Management Transition

Sono-Tek Completes Senior Management Transition

Jan 2, 2024

Dr. Christopher Coccio becomes Executive Chairman, Stephen Harshbarger appointed CEO MILTON, NY, January 02, 2024 – Sono-Tek Corporation (NASDAQ: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today announced that it has completed the senior management transition that was previously announced at the Company’s most recent annual meeting on August 24, 2023. Effective as of December 31, 2023, Dr. Christopher L. Coccio transitioned from his position as Chief Executive...

PRISM MediaWire – Weekly Press Resume – Dec. 25 to Dec. 29, 2023

PRISM MediaWire – Weekly Press Resume – Dec. 25 to Dec. 29, 2023

Dec 29, 2023

New York, December 29, 2023 PRISM MediaWire - Weekly Press Resume Dec. 25 to Dec. 29, 2023 SS Innovations Announces Strategic Partnership with Surgical Lab for Distribution in Africa https://prismmediawire.com/ss-innovations-announces-strategic-partnership-with-surgical-lab-for-distribution-in-africa/ SPZI: $53.4 million fully executed commodity contract closed https://prismmediawire.com/spzi-53-4-million-fully-executed-commodity-contract-closed/ Rodedawg Intl. Ind, Inc. (OTC: RWGI) Acquires...

Microbot Medical is Set to Progress its Liberty Robotic System into Pivotal Clinical Trial; Shares soar 60%

Microbot Medical is Set to Progress its Liberty Robotic System into Pivotal Clinical Trial; Shares soar 60%

Dec 28, 2023

New York, December 28, 2023 - Microbot Medical Inc. (Nasdaq: MBOT) has completed its GLP pivotal pre-clinical study for the LIBERTY® Endovascular Robotic Surgical System. The study, adhering to FDA guidelines and using a porcine model, successfully met all its objectives, including conducting 96 robotic navigations by three interventional radiologists. This involved evaluating target vessels and surrounding tissues with the LIBERTY system controlling various intravascular catheterization...

Enveric Biosciences Announces EB-003 as Lead Drug Candidate for Mental Health Disorders; Stock Jumps 37%

Enveric Biosciences Announces EB-003 as Lead Drug Candidate for Mental Health Disorders; Stock Jumps 37%

Dec 28, 2023

New York, December 28, 2023 - Enveric Biosciences (NASDAQ: ENVB), a biotechnology company specializing in developing novel treatments for mental health disorders, has named EB-003 as the lead candidate from its EVM301 Series. This series targets depression, anxiety, and addiction disorders. The selection of EB-003 is a key milestone for Enveric, transitioning the company from a discovery phase to a drug development phase. EB-003 is chosen for its potential to...

Immutep Advances Towards Phase III Trial for Lung Cancer Treatment with Positive Regulatory Feedback

Immutep Advances Towards Phase III Trial for Lung Cancer Treatment with Positive Regulatory Feedback

Dec 27, 2023

New York, December 27, 2023 - Immutep Limited (ASX: IMM; NASDAQ: IMMP), a trailblazing clinical-stage biotechnology company, has announced encouraging news from the Paul-Ehrlich-Institut (PEI), part of the Committee for Medicinal Products for Human Use (CHMP). This announcement marks a significant step forward in the company’s development of novel LAG-3 immunotherapies for cancer and autoimmune diseases. https://prismmarketview.com/companies/immutep-limited/#news Marc Voigt, CEO of Immutep...

PRISM MediaWire – Weekly Press Resume – Dec. 25 to Dec. 29, 2023

PRISM MediaWire – Weekly Press Resume – Dec. 18 to Dec. 22, 2023

Dec 22, 2023

New York, December 22, 2023 PRISM MediaWire - Weekly Press Resume Dec. 18 to Dec. 22, 2023 SinglePoint Rings the Opening Bell at Cboe Global Markets Exchange https://prismmediawire.com/singlepoint-rings-the-opening-bell-at-cboe-global-markets-exchange/ MindMed Advances Treatment for Generalized Anxiety Disorder https://prismmediawire.com/mindmed-advances-treatment-for-generalized-anxiety-disorder/ PRISM Analysis: Why Did Battalion Oil Shares Soar on Friday?...

HOOKIPA Stock Jumps Following $21.25M Gilead Equity Investment

HOOKIPA Stock Jumps Following $21.25M Gilead Equity Investment

Dec 22, 2023

New York, December 22, 2023 - Gilead Sciences (Nasdaq: GILD) has purchased 15 million shares of immunotherapeutics company, HOOKIPA Pharma’s (Nasdaq: HOOK), common stock for approximately $21.25 million, at a price of $1.4167 per share. Under the agreement, HOOKIPA is responsible for advancing its HIV program through the completion of a Phase 1b clinical trial. The company’s shares rose 52.65% on Thursday and 80.51% premarket on Friday. https://prismmarketview.com/companies/hookipa-pharma-inc/...

PRISM Analysis: PetVivo Holdings Achieves Distribution Milestone; Shares Soar 40%

PRISM Analysis: PetVivo Holdings Achieves Distribution Milestone; Shares Soar 40%

Dec 22, 2023

New York, December 22, 2023 - PetVivo Holdings, Inc. (Nasdaq: PETV) has achieved a distribution milestone, reporting a total of 4500 syringes of Spryng™ with OsteoCushion™ technology distributed to veterinarians in the 2023 calendar year. https://prismmarketview.com/companies/petvivo-holdings-inc/ Spryng, the company’s signature product, helps to manage lameness, joint pain and osteoarthritis in horses and small animals. Earlier this month, the company announced the sale of Spryng to more...

Ring In The New Year with Traditions and Trades: Cultural Celebrations and Stock Plays for a Prosperous Start

Ring In The New Year with Traditions and Trades: Cultural Celebrations and Stock Plays for a Prosperous Start

Dec 21, 2023

New York, December 21, 2023 - In two weeks, 2023 will be history so consider this your reminder to start figuring out a resolution that likely will be forgotten, by this time next year. New Years is celebrated in a multitude of ways based on geography, culture, or religion. However, unlike other holidays, it is one that is observed by mostly everyone around the world. As always, PRISM has you covered as we close out the year and provide you with some “go-to” resolution ideas, highlight some...

Creative Medical Technology Granted FDA Clearance for Chronic Back Pain Clinical Trial

Creative Medical Technology Granted FDA Clearance for Chronic Back Pain Clinical Trial

Dec 21, 2023

New York, December 21, 2023 - Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ) has received FDA clearance to conduct a phase 1/2 clinical trial using the company’s innovative StemSpine® treatment known as AlloStem™ (CELZ-201-DDT). https://prismmarketview.com/companies/creative-medical-technology-holdings-inc/ Timothy Warbington, CEO of Creative Medical Technology, said, “The FDA’s clearance and IRB approval allowing us to pursue this clinical trial is another...

PRISM BIOTECH IN MOTION: FDA APPROVAL FOR PANBELA THERAPEUTICS PEDIATRIC CANCER DRUG; SHARES JUMP 120%

PRISM BIOTECH IN MOTION: FDA APPROVAL FOR PANBELA THERAPEUTICS PEDIATRIC CANCER DRUG; SHARES JUMP 120%

Dec 20, 2023

New York, December 20, 2023 - PRISM MarketView, a leading provider of unbiased market insight and company news, today highlights Panbela Therapeutics, Inc. which has announced that US WorldMeds®1 (USWM) has received FDA approval of its New Drug Application (NDA) for the use of eflornithine as a maintenance therapy for high-risk neuroblastoma patients. In July 2023, Panbela divested its pediatric neuroblastoma program to USWM in an arrangement entitling Panbela to up to approximately $9.5...

PRISM MarketView: Biotech In Motion – Lipella Pharmaceuticals Celebrates Year of Success

PRISM MarketView: Biotech In Motion – Lipella Pharmaceuticals Celebrates Year of Success

Dec 20, 2023

New York, December 20, 2023 - Clinical-stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) is celebrating a year of strategic accomplishments on its first anniversary as a public company. Lipella is advancing three clinical indications and has been granted two Orphan Drug Designations by the US Food and Drug Administration (FDA). https://prismmarketview.com/companies/lipella-pharmaceuticals-inc/ Today, the company announced it has successfully completed a Type C meeting with...

Buy Now, Pay Later: Affirm Shares Jump on News of Walmart Partnership

Buy Now, Pay Later: Affirm Shares Jump on News of Walmart Partnership

Dec 20, 2023

New York, December 20, 2023 - Shares in payment network company, Affirm Holdings (Nasdaq: AFRM), jumped more than 15% on Tuesday after the company announced it would expand its partnership with Walmart to offer a Buy Now, Pay Later (BNPL) service at self-checkout kiosks at over 4,500 Walmart stores in the United States. https://prismmarketview.com/companies/affirm-holdings-inc/ https://prismmarketview.com/buy-now-pay-later-affirm-shares-jump-on-news-of-walmart-partnership/ Pat Suh, Affirm’s...

NRx Pharmaceuticals Secures IND for Urinary Tract Infection Treatment

NRx Pharmaceuticals Secures IND for Urinary Tract Infection Treatment

Dec 19, 2023

New York, December 19, 2023 - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has been granted FDA clearance for its Investigational New Drug Application (IND) for NRX-101 for the treatment of complicated Urinary Tract infections (cUTI). The company’s shares surged 25% in trading on Monday following the news. https://prismmarketview.com/companies/nrx-pharmaceuticals-inc/ Complicated Urinary Tract Infections afflict approximately 3 million Americans each year, and pathogens have...

PRISM Analysis: Why Did Battalion Oil Shares Soar on Friday?

PRISM Analysis: Why Did Battalion Oil Shares Soar on Friday?

Dec 18, 2023

NEW YORK, NY, December 18, 2023 - Shares in Battalion Oil Corporation (NYSE American: BATL) surged more than 80% on Friday after the company announced it has agreed to be acquired by Fury Resources, Inc. for $9.80 per share in cash, which represents a total transaction value of approximately $450 million. The transaction is expected to close in the first quarter of 2024. https://prismmarketview.com/companies/trio-petroleum-corp/ Battalion’s CEO, Matt Steele, commented, “It has been a pleasure...

MindMed Advances Treatment for Generalized Anxiety Disorder

MindMed Advances Treatment for Generalized Anxiety Disorder

Dec 18, 2023

NEW YORK, NY, December 18, 2023 - Biopharmaceutical company, Mind Medicine (Nasdaq: MNMD) has announced positive results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD). The trial met its primary endpoint, with MM-120 demonstrating statistically significant and clinically meaningful dose-dependent improvements. https://prismmarketview.com/companies/mind-medicine-mindmed-inc/ Robert Barrow, Chief Executive Officer and Director of MindMed,...

PRISM AdTech & Media Company Spotlight: Creative Realities Illuminates the Future of Experiential Design

PRISM AdTech & Media Company Spotlight: Creative Realities Illuminates the Future of Experiential Design

Dec 16, 2023

In the fast-paced landscape of experiential design and technology, Creative Realities Inc. seamlessly integrates the physical and digital realms in creating immersive experiences that captivate audiences across various industries. NEW YORK, NY, December 16, 2023 - Creative Realities specializes in interactive displays, immersive retail solutions, and cutting-edge content creation to reshape how individuals connect with brands and spaces. With a commitment to innovation and a client-centric...

PRISM MediaWire – Weekly Press Resume – Dec. 11 to Dec. 15, 2023

PRISM MediaWire – Weekly Press Resume – Dec. 11 to Dec. 15, 2023

Dec 15, 2023

New York, December 15, 2023 PRISM MediaWire - Weekly Press Resume Dec. 11 to Dec. 15, 2023 UAT Group Receives Financing for Iron Removal System https://prismmediawire.com/uat-group-receives-financing-for-iron-removal-system/ SKYX and GE Sign a Five-Year Renewal of a Global Licensing Master Service Agreement as SKYX Continues to Enhance its Market Penetration and Collaborations with U.S. and World Leading Strategic Companies...

“Exceptional Result”: NeuroSense Therapeutics Reports New Positive Data from ALS Trial

“Exceptional Result”: NeuroSense Therapeutics Reports New Positive Data from ALS Trial

Dec 15, 2023

NEW YORK, NY, December 15, 2023 - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has reported additional positive efficacy data from its Phase 2b trial evaluating PrimeC, the company’s lead drug candidate for amyotrophic lateral sclerosis (ALS). The company’s share price rose nearly 30% in trading on Thursday. https://prismmarketview.com/companies/neurosense-therapeutics-ltd/ Alon Ben-Noon, NeuroSense’s CEO, commented, “As we analyze the PARADIGM trial results, we continue to gain a better...

PRISM AdTech & Media Company Spotlight: Creative Realities Illuminates the Future of Experiential Design

PRISM AdTech & Media Company Spotlight: Creative Realities (CREX) Illuminates the Future of Experiential Design

Dec 14, 2023

NEW YORK, NY, December 14, 2023 - In the fast-paced landscape of experiential design and technology, Creative Realities Inc. ($CREX) seamlessly integrates the physical and digital realms in creating immersive experiences that captivate audiences across various industries. From transforming retail spaces into dynamic environments to utilizing cutting-edge technologies in interactive displays, CREX is reshaping the way we interact with the world....

Sono-Tek Announces Preliminary Record Revenue with Continued Strong Backlog for Q3 FY2024 and Increases Revenue Guidance for Fiscal Year 2024

Sono-Tek Announces Preliminary Record Revenue with Continued Strong Backlog for Q3 FY2024 and Increases Revenue Guidance for Fiscal Year 2024

Dec 14, 2023

- Sales Grew 58% YOY; Backlog Grew 68% YOY and Remains Strong at $10.4 Million; Company Projects 30% Revenue Growth for Fiscal Year ending February 29, 2024- MILTON, NY, December 14, 2023 – Sono-Tek Corporation (NASDAQ: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today announced preliminary sales and backlog for the third quarter of fiscal year 2024, ended November 30, 2023. • Preliminary sales for the third quarter of FY2024 were...

PRISM Oil & Gas: S&P Sets Fresh YTD High; Falling Gasoline Prices Play Key Role in Cooling Inflation

PRISM Oil & Gas: S&P Sets Fresh YTD High; Falling Gasoline Prices Play Key Role in Cooling Inflation

Dec 13, 2023

NEW YORK, NY, December 13, 2023 - US equities closed mostly higher on Tuesday as the S&P set a fresh year-to-date high, finishing the day at its highest level since January 2022, just 3.2% below its all-time high. Energy stocks underperformed while gasoline prices were down (6%) for the month, playing a key role in cooling inflation numbers for November. The S&P 500 Energy Index was down (1.35%) versus the S&P 500 which rose +0.14%. The XLE settled down (1.39%), the XOP fell...

FDA Grants PMA Supplement Approval for ReShape Lifesciences Lap Band; Shares Surge 100%

FDA Grants PMA Supplement Approval for ReShape Lifesciences Lap Band; Shares Surge 100%

Dec 13, 2023

NEW YORK, NY, December 13, 2023 - ReShape Lifesciences (Nasdaq: RSLS) has been granted FDA approval of a PMA supplement for the company’s next generation, enhanced Lap-Band® 2.0 FLEX. The company’s share price surged 100% in trading on Wednesday morning. https://prismmarketview.com/companies/reshape-lifesciences-inc/ Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences, said, “PMA supplement approval for our next generation Lap-Band® 2.0 FLEX is a...

PRISM MarketView Biotech in Motion Spotlight: Quoin Receives FDA Clearance for Netherton Syndrome Clinical Optimization Plan

PRISM MarketView Biotech in Motion Spotlight: Quoin Receives FDA Clearance for Netherton Syndrome Clinical Optimization Plan

Dec 13, 2023

NEW YORK, NY, December 13, 2023 - Quoin Pharmaceuticals (Nasdaq: QNRX) has received U.S. Food and Drug Administration (FDA) clearance to implement several protocol amendments to its two ongoing clinical trials for QRX003, which is a potential treatment for Netherton Syndrome, a rare genetic skin disease for which there is no cure and no approved treatments. These protocol amendments are being implemented with a view to generating an even more robust data set and potentially more...

PRISM NEXT GEN TECH COMPANY SPOTLIGHT: THE GLIMPSE GROUP’S JOURNEY INTO THE FUTURE

Dec 12, 2023

NEW YORK, NY, December 12, 2023 - An immersive technology platform company, Glimpse recently announced its plans for a strategic shift from current immersive technologies that include virtual-reality headsets, tablets and phones to spatial computing, cloud and AI-driven immersive software solutions. From cutting-edge software development to immersive content creation, Glimpse pushes the boundaries of what is possible in the realm of extended realities....

PRISM MarketView Launches Emerging AdTech and Media Index

Dec 12, 2023

Leading global companies work to strike balance between digital and traditional advertising Industry experts point to 2H 2024 for AdTech and Media IPO market to strengthen NEW YORK, NY, December 12, 2023 - PRISM MarketView, a leading provider of unbiased market insight and company news, today announces the launch of its PRISM Emerging AdTech and Media Index. With a finger on the pulse of the digital media revolution, the PRISM index is tracking emerging companies making a mark on the adtech...

MyMD Tackles Rheumatoid Arthritis with Launch of Phase 2 Trial in Early 2024

MyMD Tackles Rheumatoid Arthritis with Launch of Phase 2 Trial in Early 2024

Dec 11, 2023

NEW YORK, NY, December 11, 2023 - The FDA has cleared an Investigational New Drug Application (IND) for MyMD Pharmaceuticals (Nasdaq: MYMD) to initiate a Phase 2 clinical trial of oral MYMD-1® as a treatment for rheumatoid arthritis (RA). The company plans to launch the trial in the first quarter of 2024. Chris Chapman, M.D., president, director, and chief medical officer of MyMD Pharmaceuticals, said, “With the FDA’s recent clearance of our IND in RA, we are moving forward with plans to...

SKYX and GE Sign a Five-Year Renewal of a Global Licensing Master Service Agreement as SKYX Continues to Enhance its Market Penetration and Collaborations with U.S. and World Leading Strategic Companies

Dec 11, 2023

MIAMI, FL, December 11, 2023 - SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the "Company" or "SKYX"), a highly disruptive platform technology company with 77 pending and issued patents globally and over 60 lighting and home décor websites, with a mission to make homes and buildings become safe and smart as the new standard, today announced that it has signed with GE Technology Development, Inc. ("GE") a five-year renewal of a global licensing master service agreement to...

PRISM MediaWire – Weekly Press Resume – Dec. 04 to Dec. 08, 2023

PRISM MediaWire – Weekly Press Resume – Dec. 04 to Dec. 08, 2023

Dec 8, 2023

New York, December 08 , 2023 PRISM MediaWire - Weekly Press Resume Dec 04 to Dec. 08, 2023 Xcyte Digital Produces Second Metaverse Spectrum Business Conference and Launches Inaugural Pitch Fest https://prismmediawire.com/xcyte-digital-produces-second-metaverse-spectrum-business-conference-and-launches-inaugural-pitch-fest/ Peer To Peer Network Announces It Has Hired A PR Firm. Set To Start Major Public Relations Operation Starting In 2024...

PRISM Analysis: Stocks Making the Biggest Moves in Thursday Trading

Dec 7, 2023

NEW YORK, NY, December 07, 2023 - US equities are settling mostly higher in Thursday midday trading, with big tech broadly higher as Google ($GOOG) rallies after the company’s launch of Project Gemini, an AI model trained to behave in human-like ways. Airlines, including JetBlue ($JBLU), credit cards and chemicals are performing well. https://prismmarketview.com/prism-analysis-stocks-making-the-biggest-moves-in-thursday-trading/ Notable gainers for the day include Verint Systems ($VRNT) which...